Streamlining Oncology SMART on FHIR Prior Auth Workflows

For oncology practices facing the unique demands of high-volume, complex prior authorization, Klivira's SMART on FHIR Prior Auth solution integrates directly into your EMR, streamlining workflows and accelerating time to treatment.

Oncology prior authorization is among the most intricate and high-stakes administrative burdens in healthcare, often involving high-cost biologics, infusion therapy, radiation oncology, and frequent regimen changes. These complexities directly compete with the clinical urgency of cancer care. Klivira leverages SMART on FHIR to embed PA automation directly into the clinical workflow, addressing these challenges head-on.

The Unique Prior Authorization Landscape in Oncology

Cancer care necessitates a distinct PA cadence, where a single patient may require dozens of PA events across diagnosis, staging, treatment initiation, changes, supportive care, and surveillance. This high volume, coupled with the urgency of treatment initiation for many tumor types, makes efficient prior authorization critical. Delays in PA directly impact patient outcomes and operational efficiency.

Key Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions (e.g., immunotherapies, targeted therapies)
Advanced imaging for staging and surveillance (e.g., PET/CT, advanced MRI)
Radiation oncology procedures (e.g., IMRT, IGRT, SBRT, proton-beam therapy)
Genetic and molecular testing for treatment selection and risk stratification
Specialty oral oncolytics and supportive care medications (e.g., growth factors, antiemetics)

Transforming Oncology PA with SMART on FHIR

Klivira's SMART on FHIR integration eliminates the context-switching and manual data transfer that plague traditional PA workflows. By launching directly from within your EMR (e.g., Epic, Cerner, athenahealth, MEDITECH), our solution automatically pulls patient and encounter context via FHIR R4, ensuring accurate, real-time data for every request without leaving the clinical UI. This approach significantly reduces the administrative burden on oncologists and PA coordinators.

Benefits of In-EMR SMART on FHIR for Cancer Care

**Reduced Context-Switching:** Clinicians and coordinators remain within the EHR, improving focus and efficiency.
**Eliminated Manual Errors:** Patient and encounter data are automatically transferred via SMART launch parameters and FHIR reads.
**Accelerated Documentation Assembly:** FHIR R4 reads directly from the EHR replace screen-scraping and manual retyping, ensuring comprehensive submissions.
**Structured Outcome Write-Back:** PA decisions and status updates are written back to the EHR as structured FHIR resources (DocumentReference, Communication, Task), not free-text notes.
**Faster Time to Treatment:** Streamlined workflows and reduced delays help initiate critical cancer treatments sooner.

Klivira's Tailored Approach for Oncology Prior Authorization

Klivira's platform is engineered to navigate the unique complexities of oncology PA. We incorporate NCCN-compendium-aware policy logic to guide documentation requirements, manage regimen-level PA workflows, and intelligently route requests based on medical vs. pharmacy benefit. Our system tracks dozens of concurrent PA events per patient, from initial diagnosis through supportive care and surveillance, ensuring comprehensive coverage and minimizing treatment interruptions.

Leveraging Industry Standards for Oncology PA

**SMART on FHIR:** The foundational standard for secure, in-EMR application launch and data exchange.
**Da Vinci PAS (Prior Authorization Support):** Facilitates the electronic submission of prior authorization requests.
**Da Vinci CRD (Coverage Requirements Discovery):** Enables real-time identification of PA requirements at the point of order entry.
**Da Vinci DTR (Documentation Templates and Rules):** Guides the automated collection of necessary clinical documentation.
**US Core IG:** Provides the baseline FHIR R4 resource profiles for reading essential clinical context from the EHR.

Frequently asked questions

How does Klivira's SMART on FHIR solution handle the medical vs. pharmacy benefit split for oncology drugs?

Our platform intelligently routes oncology prior authorization requests based on the drug's benefit type. Medical benefit drugs (J-codes, IV infusions) are routed through the payer's medical PA channel (often via provider portal or X12 278), while pharmacy benefit oral oncolytics are directed through the payer's PBM and ePA partners (e.g., CoverMyMeds, Surescripts), ensuring the correct pathway is followed automatically.

What specific documentation does Klivira's SMART on FHIR app help gather for oncology PAs?

Klivira's system, informed by NCCN Clinical Practice Guidelines and Compendium, guides the collection of critical documentation. This includes pathology reports, AJCC TNM staging, relevant molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, rationale for next-line therapy, ECOG/Karnofsky performance status, and compendium citations for off-label use.

Can SMART on FHIR help with urgent oncology prior authorization requests?

Yes, SMART on FHIR significantly aids urgent oncology PA requests by embedding the workflow directly into the EMR. This eliminates context-switching and manual data transfer, accelerating documentation assembly and submission. Klivira's concurrent PA tracking also ensures that multiple urgent requests for a single patient across different treatment components are managed efficiently, minimizing delays in critical cancer care.

Which EHRs support SMART on FHIR for oncology prior authorization?

SMART on FHIR is widely supported across major EHR vendors. Klivira integrates with leading EMRs such as Epic, Cerner, athenahealth, and MEDITECH, leveraging their SMART App Launch capabilities. This allows our oncology prior authorization solution to launch seamlessly from within these clinical systems, providing a consistent user experience regardless of the underlying EHR.

How does Klivira address common oncology PA denial reasons with SMART on FHIR?

Klivira's system addresses common oncology PA denial reasons like documentation gaps, off-label use without compendium support, and step therapy requirements. By leveraging NCCN-compendium-aware policy logic, real-time coverage requirements discovery via Da Vinci CRD, and automated documentation templates via Da Vinci DTR, our platform guides users to submit complete and compliant requests, proactively mitigating denial risks.